Sector Watch: Healthcare - Sep 12 2018
This is an archive page. To See the most recent Healthcare Sectorwatch click here
IBB: $117.50 +0.06 0.05% | XBI: $96.23 -0.30 -0.31% | Updated Sep 12, 2018 04:26 PM
| HEALTHCARE STOCKS - TOP GAINERS | ||||
|---|---|---|---|---|
| XBIT XBiotech $104.8M |
2.93+0.62 666.3 K 9.2x |
27% | ||
| EVFM Evofem BioSciences $104.8M |
4.06+0.58 113.1 K |
17% | ||
| GLPG52WH Galapagos NV $5.4B |
119.71+16.97 983.9 K 11.8x |
17% | ||
| INCR52WH INC Research Holdings $163.5M |
202.90+27.90 2.6 M 1.7x |
16% | ||
| VVUS VIVUS $61.6M |
5.80+0.65 497.6 K 9.8x |
13% | ||
| HEALTHCARE STOCKS - TOP LOSERS | ||||
|---|---|---|---|---|
| PRQR ProQR Therapeutics $697.2M |
18.50-3.10 1.2 M 2.0x |
-14% | ||
| SNDX Syndax Pharmaceuticals $150.6M |
6.45-0.70 332.7 K |
-10% | ||
| TTOO T2 Biosystems $278.4M |
6.36-0.62 487.0 K |
-9% | ||
| FWP Forward Pharma A/S $142.0M |
3.01-0.29 13.0 K |
-9% | ||
| HRTX Heron Therapeutics $2.7B |
34.95-3.00 2.6 M 4.2x |
-8% | ||
Not for trading - Data delayed up to 20 minutes from last update time.
Excludes companies with market caps below $50M.
Market Caps next to company names. Trading volumes below stock prices.
NNx - unusual volume NN times the 3-month avg. volume
52WL - 52-week Low in this trading session
52WH - 52-week High in this trading session
Healthcare Stocks Related News
XBiotech Announces Addition of World Leading Cardiologist Dr. Peter Libby to its Scientific Advisory Board [globenewswire.com]Gilead and Galapagos Announce Filgotinib Meets Primary and All Key Secondary Endpoints in First Phase 3 Study in Rheumatoid Arthritis | Business Wire [businesswire.com]
GILEAD AND GALAPAGOS ANNOUNCE FILGOTINIB MEETS PRIMARY AND ALL KEY SECONDARY ENDPOINTS IN FIRST PHASE 3 STUDY IN RHEUMATOID ARTHRITIS [globenewswire.com]
ProQR Announces Closing of Underwritten Public Offering of Ordinary Shares with Full Exercise of Underwriters? Option to Purchase Additional Shares [globenewswire.com]
VIVUS Announces 1-for-10 Reverse Stock Split [globenewswire.com]
T2 Biosystems to Participate in Two Upcoming Investor Conferences Nasdaq:TTOO [globenewswire.com]
T2 Biosystems Reports Granting of Inducement Awards [globenewswire.com]
ProQR Prices $90.6 Million Underwritten Public Offering of Ordinary Shares [globenewswire.com]
Idiopathic Pulmonary Fibrosis Market - Pipeline Insights, 2018 - ResearchAndMarkets.com | Business Wire [businesswire.com]
Twentyeight-Seven Therapeutics Launches with a $65 Million Series A Funding | Business Wire [businesswire.com]
Gilead and Galapagos Announce TORTUGA Phase 2 Study of Filgotinib in Ankylosing Spondylitis Achieves Primary Endpoint | Business Wire [businesswire.com]
GILEAD AND GALAPAGOS ANNOUNCE TORTUGA PHASE 2 STUDY OF FILGOTINIB IN ANKYLOSING SPONDYLITIS ACHIEVES PRIMARY ENDPOINT [globenewswire.com]
ProQR Announces Proposed Underwritten Public Offering of Ordinary Shares [globenewswire.com]
ProQR Announces Positive Interim Results from Phase 1/2 Clinical Trial of QR-110 in LCA10 Patients, and Plans to Start a Phase 2/3 Pivotal Trial Nasdaq:PRQR [globenewswire.com]
Syndax to Present at the International Association for the Study of Lung Cancer 19th World Conference on Lung Cancer [prnewswire.com]
Disclaimer Red Acre Investments is not a registered investment advisor and the views and opinions offered herein do not constitute investment advice. Investors should always conduct their own due diligence before trading. You should assume that Red Acre is trading the securities mentioned in our Red Acre Insights, generally in accordance with the views we express, although our positions may change as news evolves. We do not undertake any obligation to update our views as market conditions evolve.
